Candel Therapeutics Added to Five Russell Value Indexes

Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, has been added to multiple value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution effective June 30, 2025. The company joined the Russell 2500 Value®, Russell Small Cap Value®, Russell 2000 Value®, Russell Microcap Value®, and Russell 3000E® Value indexes while maintaining its membership in the broad-market Russell 3000® Index since 2024. Candel’s CEO, Dr. Paul Peter Tak, highlighted that this inclusion marks an important milestone reflecting the company’s progress in clinical programs and preparations for a potential Biologics License Application for its lead product candidate CAN-2409 targeting intermediate-to-high-risk localized prostate cancer. The expansion of index presence offers enhanced visibility and engagement with the investment community, which manages approximately $10.6 trillion in assets benchmarked against Russell US indexes. These developments align with Candel’s mission to advance innovative immunotherapies across various solid tumors and address significant unmet medical needs. The Russell US Indexes reconstitution annually updates index memberships based on market capitalization, reflecting the evolving U.S. equity landscape.